ノンアルコール性脂肪性肝炎（NASH）治療及び診断の世界市場 2020年：企業別、地域別、種類・用途別

• レポートコード： • 出版社/出版日： / • レポート形態：、、ページ数はお問い合わせください。 • 納品方法：

• 販売価格（消費税別）

￥ 日本円の価格はお問い合わせください。 (0)

▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

Market Overview
The Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The most likely (base case) scenario is that the global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics sales will be xx in 2020 from Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market size is expected to grow at xx% or more annually for the next five years.

This report also researches and evaluates the impact of Covid-19 outbreak on the Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).

Market segmentation
Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market has been segmented into:
Therapeutics
Diagnostics

By Application, Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics has been segmented into:
Hospital
Clinic

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market presented in the report. This section sheds light on the sales growth of different regional and country-level Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market.

The report offers in-depth assessment of the growth and other aspects of the Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share Analysis
Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics sales, revenue and market share for each player covered in this report.

The major players covered in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics are:
Siemens Healthcare
Genfit
Cisbio
Celerion
Echosens
ZyVersa Therapeutics, Inc.
NGM Biopharmaceuticals
BioPredictive
Regeneron Pharmaceuticals, Inc.
Enterome
Among other players domestic and global, Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

レポート目次

---

1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Overview
1.1 Product Overview and Scope of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics
1.2 Classification of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics by Type
1.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Type in 2019
1.2.3 Therapeutics
1.2.4 Diagnostics
1.3 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market by Application
1.3.1 Overview: Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market by Regions
1.4.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Status and Prospect (2015-2025)
1.5 COVID-19 Outbreak: Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Industry Impact
1.5.1 COVID-19 Potential Implications for the Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics
1.5.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics
1.5.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.5.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.5.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.5.2 Opportunity Analysis in Covid-19 Crisis
1.5.3 Market Risk and Restraints
1.5.4 Market Driving Force
2 Company Profiles
2.1 Siemens Healthcare
2.1.1 Siemens Healthcare Details
2.1.2 Siemens Healthcare Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Siemens Healthcare SWOT Analysis
2.1.4 Siemens Healthcare Product and Services
2.1.5 Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
2.2 Genfit
2.2.1 Genfit Details
2.2.2 Genfit Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Genfit SWOT Analysis
2.2.4 Genfit Product and Services
2.2.5 Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
2.3 Cisbio
2.3.1 Cisbio Details
2.3.2 Cisbio Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Cisbio SWOT Analysis
2.3.4 Cisbio Product and Services
2.3.5 Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
2.4 Celerion
2.4.1 Celerion Details
2.4.2 Celerion Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Celerion SWOT Analysis
2.4.4 Celerion Product and Services
2.4.5 Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
2.5 Echosens
2.5.1 Echosens Details
2.5.2 Echosens Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Echosens SWOT Analysis
2.5.4 Echosens Product and Services
2.5.5 Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
2.6 ZyVersa Therapeutics, Inc.
2.6.1 ZyVersa Therapeutics, Inc. Details
2.6.2 ZyVersa Therapeutics, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 ZyVersa Therapeutics, Inc. Product and Services
2.6.4 ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
2.7 NGM Biopharmaceuticals
2.7.1 NGM Biopharmaceuticals Details
2.7.2 NGM Biopharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 NGM Biopharmaceuticals Product and Services
2.7.4 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
2.8 BioPredictive
2.8.1 BioPredictive Details
2.8.2 BioPredictive Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 BioPredictive Product and Services
2.8.4 BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
2.9 Regeneron Pharmaceuticals, Inc.
2.9.1 Regeneron Pharmaceuticals, Inc. Details
2.9.2 Regeneron Pharmaceuticals, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Regeneron Pharmaceuticals, Inc. Product and Services
2.9.4 Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
2.10 Enterome
2.10.1 Enterome Details
2.10.2 Enterome Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Enterome Product and Services
2.10.4 Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players Market Share
3.2.2 Top 10 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue and Market Share by Regions
4.2 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
4.3 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
4.5 South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
5 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue by Countries
5.1 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue by Countries (2015-2020)
5.2 USA Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
5.3 Canada Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
5.4 Mexico Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
6 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue by Countries
6.1 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue by Countries (2015-2020)
6.2 Germany Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
6.3 UK Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
6.4 France Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
6.5 Russia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
6.6 Italy Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue by Countries
7.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue by Countries (2015-2020)
7.2 China Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
7.3 Japan Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
7.4 Korea Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
7.5 India Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
8 South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue by Countries
8.1 South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue by Countries (2015-2020)
8.2 Brazil Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
8.3 Argentina Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics by Countries
9.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue by Countries (2015-2020)
9.2 Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
9.3 UAE Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
9.4 Egypt Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
9.5 South Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue and Market Share by Type (2015-2020)
10.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast by Type (2019-2024)
10.3 Therapeutics Revenue Growth Rate (2015-2025)
10.4 Diagnostics Revenue Growth Rate (2015-2025)
11 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Segment by Application
11.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Application (2015-2020)
11.2 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast by Application (2019-2024)
11.3 Hospital Revenue Growth (2015-2020)
11.4 Clinic Revenue Growth (2015-2020)
12 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast (2021-2025)
12.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast (2021-2025)
12.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast by Regions (2021-2025)
12.3 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Forecast (2021-2025)
12.4 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Forecast (2021-2025)
12.6 South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

---